CAPTRUST Financial Advisors
TCRR

CAPTRUST Financial Advisors’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

CAPTRUST Financial Advisors’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-200
Closed -$1K – 4454
2022
Q2 		$1K Sell
200
-420
-68% -$1.04K ﹤0.01% 4817
2022
Q1 		$2K Buy
620
+372
+150% +$1.17K ﹤0.01% 4585
2021
Q4 		$1K Buy
248
+130
+110% +$813 ﹤0.01% 4679
2021
Q3 		$1K Buy
118
+18
+18% +$254 ﹤0.01% 4528
2021
Q2 		$2K Hold
100
– – ﹤0.01% 4232
2021
Q1 		$2K Buy
+100
New +$2.73K ﹤0.01% 4097

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CAPTRUST Financial Advisors's TCRR Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q3 2022, closing a stake of 200 shares — an estimated $1K sold.

CAPTRUST Financial Advisors first reported a position in TCRR in Q1 2021 and held it in 6 quarters. The position peaked at $2K in Q1 2022. 81 funds tracked by Wall St. Rank hold TCRR as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 200 TCR2 Therapeutics Inc. Common Stock shares in Q3 2022, an estimated $1K.
  • CAPTRUST Financial Advisors first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2021 and held it in 6 quarters.
  • CAPTRUST Financial Advisors's TCR2 Therapeutics Inc. Common Stock position peaked at $2K in Q1 2022.
  • 81 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.